HLB Therapeutics Co.,Ltd.
115450
Rangering i aksjer
#18254
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
Aksjekurs
$2.02
Markedsverdi
$190.66M
Endring (1 dag)
7.96%
Endring (1 år)
-1.16%
Land
KR
Handel HLB Therapeutics Co.,Ltd. (115450)
Kategori
Healthcare
Inntekter for HLB Therapeutics Co.,Ltd. (115450)
Inntekter i Oct 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til HLB Therapeutics Co.,Ltd. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for HLB Therapeutics Co.,Ltd. fra 2016 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | $48.26M | 29.15% |
| 2024 | $37.36M | -10.01% |
| 2023 | $41.52M | 23.56% |
| 2022 | $33.60M | -8.35% |
| 2021 | $36.66M | -7.29% |
| 2020 | $39.54M | -22.56% |
| 2019 | $51.06M | 30.46% |
| 2018 | $39.14M | 143.21% |
| 2017 | $16.09M | 9.57% |
| 2016 | $14.69M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $10.11B | - |
BE
|
|
| $6.02B | - |
NL
|
